How Can We Help?
You are here:
< Back

Hyzetimibe is a pharmaceutical drug that inhibits cholesterol absorption.[1][2] It targets the NPC1-like intracellular cholesterol transporter 1.[2]

In China, it is used as a lipid-lowering agent and it has efficacy similar to ezetimibe.[3]

References

  1. ^ Ruan Z, Jiang B, Chen J, Zhang X, Lou H, Xiang M, et al. (October 2014). "Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese subjects". Journal of Clinical Pharmacology. 54 (10): 1144–1152. doi:10.1002/jcph.310. PMID 24752831.
  2. ^ a b Liao J, Yang L, Zhou L, Zhao H, Qi X, Cui Y, Ouyang D (2022). "The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial". Frontiers in Pharmacology. 13: 755469. doi:10.3389/fphar.2022.755469. PMC 8963242. PMID 35359877.
  3. ^ Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. (2023). "2023 Chinese guideline for lipid management". Frontiers in Pharmacology. 14: 1190934. doi:10.3389/fphar.2023.1190934. PMC 10498001. PMID 37711173.
Categories
Table of Contents